IDEAS home Printed from
MyIDEAS: Login to save this article or follow this journal

The Role of Peginterferon alpha-2a (40kD) Plus Ribavirin in the Management of Chronic Hepatitis C Mono-Infection

  • Dene Simpson

    (Wolters Kluwer Health | Adis, Auckland, New Zealand, an editorial office of Wolters Kluwer Health, Conshohocken, Pennsylvania, USA)

  • Monique P. Curran

    (Wolters Kluwer Health | Adis, Auckland, New Zealand, an editorial office of Wolters Kluwer Health, Conshohocken, Pennsylvania, USA)

Registered author(s):

    Although the incidence of new hepatitis C virus (HCV) infections may be declining, the prevalence of the diagnosed and treated chronic infection is set to increase over the next 2 decades because of the emergence of hepatic complications of the disease and the increased public awareness of hepatitis C and its transmission, which will prompt diagnosis and treatment of already infected individuals. Increased management costs and demands on support services are inevitable. As well as the costs of medical management of the disease and its complications, there are costs associated with the social, economic, and health-related quality-of-life (HR-QOL) issues for patients. Careful resource planning will be required, as the costs of not treating the disease are substantial. Patients with chronic hepatitis C experience a reduced HR-QOL, which is improved by the achievement of a sustained viral response (SVR; HCV RNA undetectable in serum) to treatment. Because adverse events associated with interferon-based regimens also impair the patient's HR-QOL (during treatment), avoiding unnecessary or prolonged treatment is important. Identification of likely responders to treatment and treating patients for the minimum period of time with the best tolerated and most efficacious drugs could improve compliance and treatment outcomes and contribute to the effective use of available resources. A combination of subcutaneous peginterferon plus oral ribavirin has superseded unmodified interferon-alpha-based therapy for chronic hepatitis C, and is approved for the treatment of treatment-naive patients with chronic hepatitis C and compensated liver disease. Two peginterferons are available, peginterferon alpha-2a (40kD) [Pegasys(R)] and peginterferon alpha-2b (12kD) [PegIntron(R)], and both have shown significantly higher SVR rates than unmodified interferon-alpha when each was administered with ribavirin. There have been no head-to-head comparisons of these two agents in clinical trials. There are data from a study of peginterferon alpha-2a (40kD) plus ribavirin supporting the treatment of patients with chronic hepatitis C and persistently normal ALT activity. Achievement of an SVR with the peginterferon alpha-2a (40kD) combination was associated with an improvement in the HR-QOL of patients regardless of ALT activity. The efficacy and HR-QOL benefits of peginterferon alpha-2a (40kD) plus ribavirin for chronic hepatitis C may outweigh the increased acquisition costs of the drug, and this combination is estimated to be cost effective compared with unmodified interferon-based regimens (or no treatment in patients with chronic hepatitis C and persistently normal ALT activity).

    If you experience problems downloading a file, check if you have the proper application to view it first. In case of further problems read the IDEAS help page. Note that these files are not on the IDEAS site. Please be patient as the files may be large.

    File URL:
    Download Restriction: Pay per view

    File URL:
    Download Restriction: Pay per view

    As the access to this document is restricted, you may want to look for a different version under "Related research" (further below) or search for a different version of it.

    Article provided by Springer Healthcare | Adis in its journal Disease Management & Health Outcomes.

    Volume (Year): 14 (2006)
    Issue (Month): 5 ()
    Pages: 303-320

    in new window

    Handle: RePEc:wkh:dmhout:v:14:y:2006:i:5:p:303-320
    Contact details of provider: Web page:

    No references listed on IDEAS
    You can help add them by filling out this form.

    This item is not listed on Wikipedia, on a reading list or among the top items on IDEAS.

    When requesting a correction, please mention this item's handle: RePEc:wkh:dmhout:v:14:y:2006:i:5:p:303-320. See general information about how to correct material in RePEc.

    For technical questions regarding this item, or to correct its authors, title, abstract, bibliographic or download information, contact: (Dave Dustin)

    If you have authored this item and are not yet registered with RePEc, we encourage you to do it here. This allows to link your profile to this item. It also allows you to accept potential citations to this item that we are uncertain about.

    If references are entirely missing, you can add them using this form.

    If the full references list an item that is present in RePEc, but the system did not link to it, you can help with this form.

    If you know of missing items citing this one, you can help us creating those links by adding the relevant references in the same way as above, for each refering item. If you are a registered author of this item, you may also want to check the "citations" tab in your profile, as there may be some citations waiting for confirmation.

    Please note that corrections may take a couple of weeks to filter through the various RePEc services.

    This information is provided to you by IDEAS at the Research Division of the Federal Reserve Bank of St. Louis using RePEc data.